Mind the gap: potential for rebounds during antiangiogenic treatment breaks.
VEGF pathway inhibitors have shown benefits in many cancers, yet many (often controversial) questions remain about whether vascular and tumor regrowth can occur when therapy is stopped. Marked increases in endothelial cell proliferation could play a role in putative rebounds, potentially influencing overall efficacy, dosing schedules, and presurgical intervention strategies.
Genitourinary Program, Roswell Park Cancer Institute, Buffalo, NY, USA.
John M L
JM
Ebos
Roberto
R
Pili
D000818:Animals; D049109:Cell Proliferation; D002986:Clinical Trials as Topic; D042783:Endothelial Cells / Q000166:cytology*; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000628:therapy*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000378:metabolism
D042461:Vascular Endothelial Growth Factor A